|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Other investment | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit) | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued research and development costs | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Operating lease liability, current | ||||||||||||||||||||
| Warrant liability, related party | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long term liabilities: | ||||||||||||||||||||
| Accrued other liabilities, non-current | ||||||||||||||||||||
| Operating lease liability, non-current | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Commitments and contingencies (Note 11) | ||||||||||||||||||||
| Preferred stock | ||||||||||||||||||||
| Series Seed Convertible Preferred Stock | ||||||||||||||||||||
| Series A Convertible Preferred Stock | ||||||||||||||||||||
| Series B Non-voting Convertible Preferred Stock | ||||||||||||||||||||
| Total preferred stock | ||||||||||||||||||||
| Stockholders' equity (deficit): | ||||||||||||||||||||
| Common stock, no par value; 700,000,000 and 122,363,552 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 45,541,358 and 1,244,400 shares issued and outstanding as of September 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Paid-in capital | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders' equity (deficit) | ||||||||||||||||||||
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | ||||||||||||||||||||
Loading...